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ABSTRACT
Introduction: It is unclear as to whether
human or long-acting analog insulins
represent the most efficient use of health and
non-healthcare resources in the management of
type 2 diabetes mellitus (T2DM). The aim of this
study was to evaluate the value for money
relationship associated with the use of these
insulins in the UK setting.
Methods: A literature search was performed for
studies reporting expenditure associated with
the use of human and analog insulins. Data
from this review informed a budget impact
assessment model. Costs were converted to a
common currency and results are reported in
2011 British pounds sterling (GBP) values.
Results: Annual diabetes-related medication
expenditure and patients total expenditure
associated with the management of T2DM
were estimated to be £397 million and £3,901
million, respectively. Substitution of human
insulin for analog insulins was associated with
a drug acquisition cost saving of between £5
million and £23 million each year. Overall,
though, total expenditure increased significantly
with increased use of human insulin by £34
million to £136 million each year depending on
the degree of substitution.
Conclusions: On the face of it, analog insulins
are more expensive, prompting questions about
potential cost savings to health services in
the UK from direct substitution to the less
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expensive human preparation. The current
analysis illustrates that the increased use of
human insulin and decreased use of analog
insulin would, however, increase the overall net
societal cost of managing insulin-treated
patients with T2DM. Governments and
decision makers should consider that total
healthcare expenditure would not necessarily
fall when decisions are based solely on the use
of cheaper products.
Keywords: Costs and cost analysis; Diabetes
mellitus; Human insulin; Insulin analog;
Resource allocation; Type 2 diabetes
INTRODUCTION
Background
There are an estimated 346 million people with
diabetes worldwide. Type 2 diabetes mellitus
(T2DM) is the most common, accounting for
90% of the diabetic population [1]. Unlike people
with type 1 diabetes, who require insulin, people
with T2DM can initially manage their condition
without pharmacological intervention. However,
the natural history of T2DM, characterized
by progressive decline in beta cell function,
results in an inevitable need for multiple
pharmacotherapies including oral antidiabetic
drugs (OADs), insulin, or both, in order to
optimize blood glucose control [2]. Indeed, over
the course of the UK Prospective Diabetes Study
(UKPDS),[50% people treated with sulfonylureas
required additional insulin to maintain fasting
plasma glucose levels\6 mmol/L, within 6 years
of T2DM diagnosis [3].
There is a growing emphasis on insulin
management. Insulin initiation early within
the natural history of T2DM is now endorsed
by professional bodies including the American
Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD) [4].
The growing prevalence of T2DM and data
suggesting a reduction in mortality in people
with T2DM indicate that the use of insulin for
the management of glucose control in people
with T2DM will continue to rise [5].
Accordingly, there is widespread interest
in evaluating the safety, efficacy, cost-
effectiveness, and affordability of alternative
insulin treatments. A number of insulin
products are available that address variability
in patient phenotypes, preference, and response
to treatment. Preparations are available that
more closely mimic normal insulin production
(short-acting) or provide a continuous supply of
insulin over a longer time period (intermediate-
and long-acting).
Recent Evidence
The intermediate-acting human isophane
insulin (NPH) and the long-acting analog
insulins glargine and detemir have been the
subject of recent reviews that have brought into
question the clinical benefits and economic
value of long-acting insulin analogs compared
to human insulin [6–8]. These reviews suggest
that insulin analogs and NPH are similarly
effective in terms of glycemic control;
however, clinical and economic value should
also be assessed from the perspective of other
clinical endpoints, including hypoglycemia [9].
Hypoglycemia is a recognized consequence of
intensification of glucose control [10–12]. In
people with T2DM receiving insulin therapy for
\2 years, nearly 50% of patients reported
recurrent symptomatic hypoglycemia, while
20% of patients reported at least one episode
of severe hypoglycemia [13]. Hypoglycemia has
significant clinical and economic implications,
thus an increase in the rate of hypoglycemia
with human compared to analog insulin may
52 Diabetes Ther (2013) 4:51–66
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exert significant health economic implications
[14–17]. Further, it is important to remember
that these reviews were based on the results of
randomized controlled trials that evaluated
highly selected patient populations under
tightly controlled conditions [6, 7]. As such,
these conclusions may not truly reflect patient
outcomes as observed in clinical practice nor
reflect the actual value of human insulin
compared to analog insulin.
Nonetheless, a natural question arising from
these reviews is whether health systems could
achieve productivity savings from switching to
human insulin. A recent analysis characterizing
patterns of insulin prescriptions suggested that
the UK National Health Service (NHS) would
have achieved savings of £635 million from
2000 to 2009, had all prescriptions been for
human insulin [8]. Thus, on the face of it,
starting people with T2DM on human insulin or
even converting people from analog insulin
may reduce health expenditure. However, there
are other relevant considerations when
informing decisions around the optimization
of health spending and medication choice in
the treatment of T2DM.
Acquisition Costs and Total Expenditure
A comparison of product acquisition costs
alone, that is the cost of prescribed
medications to the NHS, fails to address the
much larger set of costs associated with the
management of T2DM. The other parameters
that should be considered in a value for money
evaluation include both direct and indirect
costs. The direct costs for diabetes patients
include publicly funded healthcare, most often
in terms of primary and secondary care,
prescribed medications, and other treatments.
The indirect costs incurred by patients, their
families, and caregivers include time spent in
managing the symptoms of T2DM and
adjusting their lifestyles to the needs of the
condition; for example, they incur out-of-
pocket expenses associated with transport to
healthcare services and in paying for specialist
foods used to regulate metabolic activity. When
the full spectrum of cost is considered, then
medication costs, OADs, and insulin account
for only 7% of total healthcare expenditure in
the management of T2DM, while diabetes-
related late complications and hospitalizations
are the single greatest determinant of costs [18].
Hence, from the perspective of informing public
spending decisions, an evaluation of acquisition
costs alone does not provide a true sense of the
total economic consequences associated with
insulin choice.
Aims
The purpose of this study was to extend the
analysis of human versus analog basal insulin to
illustrate the limitations of analyses that, we
argue, improperly restrict the decision context
to the results of randomized trials and drug
acquisition cost. We aim to inform questions
surrounding the ‘‘value for money’’ associated




The authors adopted a societal perspective by
considering the direct and indirect costs
associated with T2DM. The authors developed
a prevalence-based budget impact assessment
model that characterizes components of
resource utilization (costs) associated with
the periods surrounding insulin initiation,
defined by the need for resources used in the
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management of T2DM. Evidence informing the
budget impact model came from a literature
search of PubMed using the keywords: ‘‘human
insulin’’ OR ‘‘NPH’’ OR ‘‘glargine’’ OR ‘‘detemir’’
AND ‘‘cost’’ OR ‘‘resource utilization’’. Study
titles and abstracts were first reviewed followed
by complete manuscripts. Included studies were
from 2006 onwards, an arbitrary cut-off to help
ensure extracted data reflected contemporary
clinical practice. The authors did not have
access to a translation service and so only
studies written in the English language were
considered. Studies had to describe resource use
(costs) associated with the use of human and
analog insulin or either insulin alone. Data on
total costs and cost components were extracted
from each included study. Economic modeling
studies were excluded as it was anticipated that
the primary data contained in economic
modeling studies could not be extracted
readily or consistently.
Data from the reviewed studies was
summarized for human insulin and long-acting
analog insulins. The results for the human and
analog insulins were stratified according to
whether they were direct costs: hypoglycemia-
related, medications (diabetes or other), medical
services (diabetes or other); or indirect costs.
Analytical Approach
Data from the included studies was summarized
for each direct and indirect resource category
associated with the management of T2DM and
use of basal insulin. Data for total expenditure
and diabetes-related medication expenditure
were adjusted to 2011 values and standardized
to British pounds sterling (GBP) in references to
temporal changes in country exchange rates
[19]. A quasi meta-analysis was undertaken
whereby the point estimates from each study
were weighted by the proportion of subjects in
each insulin group. A full meta-analysis was not
permitted, as the included studies did not
consistently report variation around mean
estimates. The data included in the analyses
originated from several countries; to reflect the
UK setting an adjustment was made in the
budget impact calculations by scaling study
estimates by the ratio of total healthcare
expenditure as a percentage of output [gross
domestic product (GDP)] in the UK to total
healthcare expenditure as a percentage of GDP
in the other country. Values obtained from
published sources indicated the US spends
16.0% of its total GDP on healthcare,
Germany 10.4%, and the UK 8.4% [20]. Point
estimates for annual diabetes-related
medication expenditure and total expenditure
were obtained by multiplying annualized per-
person estimates of expenditure by estimates of
the prevalence of T2DM in the UK, the
proportion of the prevalent population using
insulin therapy, and the proportion of people
prescribed human and analog insulin.
RESULTS
Literature Review
The literature review identified 161 studies and
a variety of resource utilization categories
(Table 1). Of the reviewed studies nine were
considered relevant (Tables 2, 3) [14, 21–28]. All
studies were industry-sponsored. Details of the
included studies including number of people,
treatment setting, study year, study design and
follow-up period, mean age, and primary
objective, are reported in Table 4 [14, 21–28].
Budget Impact Assessment
In the budget impact assessment, total diabetes-
related medication expenditure per person was
54 Diabetes Ther (2013) 4:51–66
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15% lower each year with human insulin versus
analog insulin. Once all relevant costs were
factored into the analysis, the total annual
expenditure associated with human insulin
was 8% higher at an individual level compared
to analog insulin, and this includes the cost of
diabetes-related medications.
The authors estimate that for the UK-
prevalent population of T2DM, patients total
and diabetes-related medication expenditure is
£3,901 and £397 million, respectively, each
year. The authors estimate that medication
acquisition cost savings in the order of £26
million a year might be achieved if all analog
insulin users converted to human insulin, but
that any savings in medication acquisition cost
would be consumed/offset by the estimated
increase in overall treatment costs to
individuals and the NHS of £284 million each
year.
Across modeled scenarios whereby there is a
positive utilization of each insulin type, a 10%
increased use of human insulin and a
proportional decrease in the use of long-acting
analog insulin would save the NHS around £5
million each year on drug acquisition cost, but
the net overall cost to the NHS would increase
by £34 million each year (Table 5 [1, 6, 8, 29],
Fig. 1). For scenarios ranging from a 10% to
40% increased use of human insulin and an
equivalent reduction in the use of analog
insulins from current levels, this equates to a
potential saving between £5 million and
£23 million each year on drug acquisition
cost, but the net overall cost to the NHS would
increase by £34 million to £136 million each
year.
DISCUSSION
In the management of T2DM a complicated
picture arises when considering the relationship
between overall clinical benefit (for example,
glycemic control vs. hypoglycemia), treatment
options (comparative effectiveness), and



































A1c glycated hemoglobin, DSN diabetes specialist nurse,
OADs oral antidiabetic drugs, SMBG self-monitoring
blood glucose
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consequent direct healthcare expenditure
and indirect costs. Many clinical studies—
randomized and observational—have attempted
to address the effectiveness and comparative
effectiveness of technologies used in the
management of T2DM [6, 30]. Certainly,
many individual studies, mostly observational in
nature, have often addressed narrow and
disparate research questions about the financial
costs associated with the management of
T2DM. The aim of this study was to provide
an understanding of the likely expenditure
associated with T2DM and the use of different
basal insulin products across patients, their
families, health services, and society.
Comparison to Other Studies
In the UK it has been estimated that around
£3.5 billion is spent on diabetes each year
[31, 32]. Looking across the various levels of a
health service and more broadly into society,
the authors estimate the total expenditure
associated with T2DM to be £3.9 billion each
year. Our analysis of human and analog insulins
suggests that total annual diabetes-related
medication expenditure is £397 million.
This analysis extends recent reports of the
value for money relationship between human
and analog insulins by delineating medication
acquisition costs and total costs associated with
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– – – – 1,069 1,069 1,069
Medications/
associated devices
– 1,460 1,694 – – 1,460 1,694
Medical costs – 1,617 – – – 1,617 1,617
Indirect costs – – 10 1,186 35 10 1,186
Total 5,493 3,076 – – – 3,076 5,493
Total costs
Medications – 5,875 1,949 – – 1,949 5,875
Medical costs – 14,803 802 – – 802 14,803
Indirect costs – – 10 1,186 – 10 1,186
Total 18,347 20,679 2,761 – – 2,761 20,679
Weighted average across three treatment settings which were deﬁned as the severe event being treated and managed by a
‘‘family member/friend’’, ‘‘community healthcare worker’’ or ‘‘in hospital’’
Historical exchange rates used for conversion [19]
GBP British pounds sterling, GDP gross domestic product, LL lower limit, OADs oral antidiabetic drugs, UL upper limit
a Values based on estimates post-insulin initiation, annualized
b Including insulins, OADs, blood glucose self-testing devices, pens and needles required for insulin administration
c Multi-country study of type 1 and 2 diabetes. Values refer to type 2 population only
d Multi-country study, UK data reported
e Data are point estimate (mean) values. Range refers to spread of mean values across included studies before adjustment for
variation in GDP per country or study size
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human versus analog insulin use in the UK. This
analysis suggests the maximum total cost saving
if all users of analog insulin switched to human
insulin would be around £260 million over a
10-year period, less than half (41%) of recent
estimates suggesting total cost savings over the
last 10 years might have been in the region of
£635 million [8]. Furthermore, the authors
show that any cost saving associated with the
acquisition cost of the relatively less expensive
human insulin is outweighed by the utilization
of other healthcare resources and indirect costs.
Limitations
There are a number of limitations of this
research that may impact the interpretation of
the authors findings. Firstly, in restricting the
literature search to recent studies in English and
by excluding economic modeling studies there































– 1,813 1,325 1,205 1,224 2,700 – – 1,205 2,700
Medical costs – 831 – – – 3,196 – – 831 3,196
Indirect costs – 0 – – – 1,186 35 0 1,186
Total 5,253 2,644 – – – – – – 2,644 5,253
Total costs
Medications – 5,993 1,760 – – 6,758 – – 1,760 6,758
Medical costs – 11,813 739 – – 8,052 – – 739 11,813
Indirect costs – – 0 – – – 1,186 – 0 1,186
Total 16,576 17,806 2,499 – – 15,854 – – 2,499 17,806
Weighted average across three treatment settings which were deﬁned as the severe event being treated and managed by a
‘‘family member/friend’’, ‘‘community healthcare worker’’ or ‘‘in hospital’’
Historical exchange rates used for conversion [19]
GBP British pounds sterling, GDP gross domestic product, LL lower limit, OADs oral antidiabetic drugs, UL upper limit
a Values based on estimates post insulin initiation, annualized
b Including insulins, OADs, blood glucose self-testing devices, pens and needles required for insulin administration
c 180 day follow-up period, annualized
d Multi-country study of type 1 and 2 diabetes. Values refer to type 2 population only
e Multi-country study, UK data reported
f Data are point estimate (mean) values. Range refers to spread of mean values across included studies before adjustment for
variation in GDP per country or study size
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is a chance the authors have excluded
potentially relevant studies from their
estimations. Secondly, a full meta-analysis was
not possible because the studies identified from
the literature review did not consistently report
variation around point estimates [only two of
the nine studies reported estimates of variation,
i.e., standard deviation (SD) or standard error
(SE)]. Thus it was not possible to estimate the
statistical heterogeneity between studies and
therefore their similarity. In using a weighted
average of point estimates, with study size as the
weighting factor, we are able to quantify the
cost implications associated with insulin use,
which may be useful to other researchers and
decision makers. The authors do stress,
however, that caution should be exercised
when interpreting their findings given that
there may be important differences between
the combined studies; the table of study details
(Table 4) may be useful in addressing this
limitation. Thirdly, the nature of study
sponsorship (i.e., industry-sponsored research)
may impact the results of an individual study
and hence the synthesis of estimates across
studies. One approach in addressing this type of
bias is to exclude studies whose sponsorship
may directly or indirectly affect study findings.
The studies identified from the current
literature review were all industry-sponsored.
On this basis, the authors could not exclude
industry-sponsored studies. The authors note
this as a limitation of the available data and a
potential source of bias in their study estimates.
Cost Drivers
Since the primary therapeutic advantage of the
analog insulins relates to a reduction in
hypoglycemia [33], potential cost drivers in
this context include excess blood glucose
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to suboptimal insulin dosing and therapy
nonadherence consequent upon hypoglycemia
[34], and the costs associated with
hypoglycemia-associated hospitalization [15,
35, 36]. In explaining why the more expensive
long-acting insulin products can be cost saving
in terms of total expenditure, the authors
speculate to the association between the use of
analog insulins and cost offsets associated
with a reduction in hypoglycemic events and
reduced frequency of injections from twice to
once daily.
Hypoglycemia represents a major clinical
barrier to achieving glycemic control in people
with diabetes and has a major economic impact
on overall healthcare spending. Over 30% of
people with T2DM treated with insulin
experience symptomatic hypoglycemia [37],
while data from recent mega trials evaluating
the potential outcome benefit associated
with intensification of glucose control has
demonstrated an association between severe
hypoglycemia and an increased risk of
diabetes-related complications [38]. Furthermore,
a recent retrospective observational analysis of
[860,000 people with T2DM which examined
the relationship between hypoglycemic
events and acute cardiovascular events over
a 2-year period demonstrated that after
controlling for multiple confounders, patients
with documented outpatient hypoglycemic
events had a 79% higher regression-adjusted
odds [odds ratio 1.79; confidence interval (CI)
1.69–1.89] of acute cardiovascular events than
patients without documented hypoglycemic
events. In addition, those patients who
experienced hypoglycemia incurred twofold
greater health-related expenditure [15].
Further studies are required to confirm these
findings.
Hypoglycemia results in significant resource
utilization form a healthcare perspective. This
concept is supported by the fact that
hypoglycemia is the primary diagnosis
resulting in 14,437 hospital admissions in the
UK between 2009 and 2010, accounting for a
total bed occupancy of 76,569 days [39].
Hypoglycemia also has a significant impact
on the quality of life of people with diabetes
as well as therapy adherence. Symptomatic
hypoglycemia is associated with reduced
therapy adherence, treatment satisfaction, and
Fig. 1 Budget impact associated with increased use of human/analog insulin (2011 GBP)
62 Diabetes Ther (2013) 4:51–66
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results in many people intentionally
maintaining a state of hyperglycemia, with
people with T2DM reducing their insulin dose
57.5% of the time following severe
hypoglycemia, and 43.0% of the time
following mild or moderate hypoglycemia
[16, 17, 40, 41]. Indeed, fear of hypoglycemia
in younger people with type 1 diabetes is greater
than the fear of developing the later
complications of diabetes [42]; it is possible
that this relationship could carryover to people
with T2DM.
A reduction in the frequency of nocturnal
hypoglycemia is one the key advantages of the
insulin analogs (insulin detemir and insulin
glargine), compared to human insulin. This
represents a major consideration when
considering the value for money proposition
of these insulin preparations since almost 50%
of all episodes of severe hypoglycemia occur
at night during sleep [43]. Nocturnal
hypoglycemia results in significant detrimental
effects on mood and wellbeing the following
day and has the greatest socioeconomic
consequences from the perspective of reduced
productivity and lost time at work, and
represents a particular barrier to optimal
insulin dose titration [14, 43, 44]. In addition,
nocturnal hypoglycemia has been causally
associated with acute sudden death [45], while
recurrent nocturnal hypoglycemia is linked to
the development of hypoglycemia unawareness,
which in turn is associated with a higher rate of
severe hypoglycemia [46].
Differences in rates of hypoglycemia
between human and analog insulins were
conflated in the results of the individual
studies that informed our cost analysis. In the
discussion the authors have only speculated to
theoretically plausible clinical explanations of
cost drivers. As such, we cannot directly
attribute our expenditure estimates to different
cost drivers. Instead we have used a linked
evidence approach [47] to highlight the likely
role of hypoglycemia as an overall cost driver
and explanation for our key finding that human
insulin is, on balance, likely to be more
expensive than analog insulins.
CONCLUSIONS
It is difficult to gain a sense of the extent
of expenditure made by individuals and
governments in managing T2DM. The authors
find that direct and indirect expenditure
is significant. Diabetes-related medication
expenditure is generally lower in users of
human insulin compared to users of long-
acting analog insulin. Overall, though, the use
of analog insulins was cost saving compared to
human insulin. These productivity gains may
be related to fewer hypoglycemic events.
The value for money of human insulin and
analog insulins does not rest at medication
acquisition costs alone. Governments and
decision makers should consider that total
healthcare expenditure will not necessarily
decrease when decisions are based solely on
the use of cheaper products. By factoring in the
clinical benefits of insulin analogs in contrast
to their higher costs, we estimate that a
paradigm shift towards increased use of
human insulin and decreased use of analog
insulin would on average increase the net
societal cost of managing insulin-treated
patients with T2DM.
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